Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
6R BH4 · 1 trial · 2 indications
Early morning urine specimens were collected to calculate albumin and creatinine ratio (albuminuria) at 6 and 12 weeks of therapy.
| Arm | Type | Description |
|---|---|---|
| 6R BH4 | EXPERIMENTAL | Subjects will receive 6R-BH4 400mg bid for 6 weeks, sequentially followed by 6R-BH4 plus Vitamin C 500mg bid for another 6 weeks. Patients will have scheduled visits at Weeks 0,3,6,9 and 12, with an exit-visit at week 16. Albuminuria will be assessed in 24-hour urine collections as well as early morning spot urine samples for albumin:creatinine ratio. Blood and urine will be tested for routine clinical laboratory tests, blood nitric oxide (NO), and also archived for later assays for special biomarkers. The primary outcome will be level of albuminuria as measured in a 24-hour urine collection at 6 and 12 weeks of therapy. Secondary outcomes will include urine albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), and blood pressure . |
| Name | Type | Description |
|---|---|---|
| 6R BH4 | DRUG | 400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms |
| Vitamin C | DIETARY_SUPPLEMENT | 500 mg Vitamin C oral BID for another 6 weeks |
Inclusion Criteria: * Patients with controlled hypertension (blood pressure (BP) less than 150/90 mmHg) using standard antihypertensive medications. * Stable chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) 40-90 ml/min/173m2 by the abbreviated Modification of Diet in R...
Top 20 of 25 competitors
6R BH4 is an investigational small molecule being studied for kidney disease and hypertension. In clinical trials, it has been evaluated for its effects on blood pressure in patients with poorly controlled systemic hypertension and in patients with chronic kidney disease and albuminuria. It is not approved and remains in clinical development.
6R BH4 is being developed by BioMarin Pharmaceutical Inc., a biopharmaceutical company traded on the NASDAQ under the ticker BMRN. The company has sponsored Phase 2 clinical trials of the drug in the United States.
6R BH4 is in Phase 2 clinical development. Two Phase 2 trials have been completed, one in hypertension and one in kidney disease with albuminuria. The drug is investigational and has not been approved by regulatory authorities.
6R BH4 has been studied in two completed Phase 2 trials. NCT00325962 examined its effects on blood pressure in 84 adults with poorly controlled systemic hypertension. NCT00625820 studied the drug in 17 adults with chronic kidney disease and albuminuria. Both trials were conducted in the United States.
6R BH4 is also known as tetrahydrobiopterin, and the clinical trial NCT00625820 refers to the drug by that name. It is a small molecule being investigated for its potential effects on blood pressure and kidney function in patients with hypertension and chronic kidney disease.